QuantCapitol. Congressional Trading Intelligence

Updated 2026-11-05 17:03 UTC · Public disclosure record

CRITICKER

Carters Inc.

INSUFFICIENT DATA stock

Congress has disclosed 0 buys and 1 sell of CRI (Carters Inc.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.

Activity Congressional Activity

0
Buy
1
Sell
-1
Net
1
Active politicians
Price & congressional trades
Buy Sell

Fundamentals · FY2026 Valuation

Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for —. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.

P/E
6.91
no sector median
how it's calculated
P/E = price ÷ earnings per share
$31.54 ÷ $4.56 = 6.91
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
P/B
1.1
no sector median
how it's calculated
P/B = price ÷ book value per share
$31.54 ÷ $28.73 = 1.1
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
EV/EBITDA
4.18
no sector median
how it's calculated
EV/EBITDA = (market cap + net debt) ÷ EBITDA
($1.2B + $0.1B net debt) ÷ $0.3B = $1.3B ÷ $0.3B = 4.18
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.

1 trades Recent Congressional Trades

Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.

PoliticianChamberTypeOwnerDateDisclosure lagPrice move
in that
window
AmountScoreSource
Michael Conaway House SELL Spouse 2016-09-12 3 days — $1K–$15K 75.9 ↗ filing

Corporate insiders · SEC Form 4 Insider Activity

What the company's own officers and directors did in CRI — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →

0
Congress trades with insider convergence
0
…with insider divergence
13
Insider open-market trades

Of the congressional trades in CRI, 0 coincided with corporate insiders moving the same way within 60 days, and 0 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.

DateInsiderRoleTypeSizeSource
2024-03-13 Jenkins Jeff Other SELL $91K ↗ EDGAR
2024-03-06 Hipp Mark Director SELL $153K ↗ EDGAR
2023-12-14 CASEY MICHAEL DENNIS C-suite SELL 10b5-1 $2.2M ↗ EDGAR
2023-12-14 CASEY MICHAEL DENNIS C-suite SELL 10b5-1 $4.4M ↗ EDGAR
2023-12-08 D'Emilio Julie Other SELL $246K ↗ EDGAR
2023-11-17 Pivar Ben Other SELL $22K ↗ EDGAR
2023-11-03 Lynch Brian C-suite SELL 10b5-1 $236K ↗ EDGAR
2023-11-03 Lynch Brian C-suite SELL 10b5-1 $841K ↗ EDGAR
2023-11-03 Westenberger Richard F. C-suite SELL 10b5-1 $263K ↗ EDGAR
2023-11-03 Krugman Kendra Other SELL $140K ↗ EDGAR
2023-11-02 Lynch Brian C-suite SELL 10b5-1 $282K ↗ EDGAR
2023-08-25 Jenkins Jeff Other SELL $243K ↗ EDGAR
2023-08-04 Wilson Jill Other SELL $150K ↗ EDGAR

Combined timeline — Congress & insiders

Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.

DateWhoTypeSize
◆ insider 2024-03-13 Jenkins Jeff Other SELL $91K
◆ insider 2024-03-06 Hipp Mark Director SELL $153K
◆ insider 2023-12-14 CASEY MICHAEL DENNIS C-suite 10b5-1 SELL $2.2M
◆ insider 2023-12-14 CASEY MICHAEL DENNIS C-suite 10b5-1 SELL $4.4M
◆ insider 2023-12-08 D'Emilio Julie Other SELL $246K
◆ insider 2023-11-17 Pivar Ben Other SELL $22K
◆ insider 2023-11-03 Lynch Brian C-suite 10b5-1 SELL $236K
◆ insider 2023-11-03 Lynch Brian C-suite 10b5-1 SELL $841K
◆ insider 2023-11-03 Westenberger Richard F. C-suite 10b5-1 SELL $263K
◆ insider 2023-11-03 Krugman Kendra Other SELL $140K
◆ insider 2023-11-02 Lynch Brian C-suite 10b5-1 SELL $282K
◆ insider 2023-08-25 Jenkins Jeff Other SELL $243K
◆ insider 2023-08-04 Wilson Jill Other SELL $150K
Congress 2016-09-12 Michael Conaway SELL $1K–$15K

FAQ Common questions

How much has Congress traded CRI?

0 disclosed buys and 1 sells of CRI (Carters Inc.) appear in official congressional financial disclosures.

Is it legal for members of Congress to trade CRI?

Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.

Where does this data come from?

Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.

About this data. Sourced from official House Clerk and Senate eFD financial disclosures (Senate via a maintained community mirror — see project documentation). Transaction amounts are reported as ranges, not exact figures. Interest scores, consensus labels, and backtested performance are proprietary analytical calculations based on public data and are not investment advice. Backtested performance is a hypothetical simulation, not actual portfolio performance.